The expanding field of targeted treatment relies heavily on recombinant cytokine technology, and a detailed understanding of individual profiles is paramount for fine-tuning experimental design and therapeutic efficacy. Specifically, examining the attributes of recombinant IL-1A, IL-1B, IL-2, and IL-3 highlights important differences in their struc